CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA213225 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA213225.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical
1

Critical

100%

0

High

0%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: VOBRIG (LEUPROLIDE ACETATE) — Type 5 - New Formulation or New Manufacturer

Policy FDA-NDA213225 · Oncology

Critical

VOBRIG (leuprolide acetate) is a new injectable formulation of an established GnRH agonist, approved under NDA213225 as a Type 5 submission by Sun Pharmaceutical Industries Limited. As an injectable a

View alert

Audit documentation

Building an audit file that includes FDA-NDA213225?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription